Universe Pharmaceuticals INC

UPC Healthcare Drug Manufacturers Specialty & Generic

Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.

3.97 0.18 −4.34%
Market cap
$20.9M
P/E
0.0×
Fwd P/E
4.1×
Dividend yield
—
F-score
4/9
Altman Z
0.63
Beneish M
−2.56
Dividend safety
n/a
Mar '26 Sep '25 Mar '25 Sep '24 Older periods
ROE
0.00% 0.00% 0.00% 0.00%

+8 more TTM periods

ROA
0.00% 0.00% 0.00% 0.00%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
0.00% 0.00% 0.00% 0.00%
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(17.21) (15.10) (8.71) (6.37)
Capital Expenditures
(0.91) (0.67) (0.45) (0.36)
Other line items
Cash ROIC
(18.26%) (15.25%) (7.90%) (7.68%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Operating CF/Net income
0.00 0.00 0.00 0.00
Depreciation/Fixed assets
0.40 0.15 0.46 0.15
Capex/Depreciation
(0.61) (0.44) (0.30) (0.24)
Operating CF per Share
0.00 0.00 0.00 0.00
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates